Article

Abraxane approved for metastatic pancreatic cancer

Elizabeth whittington blog image

Because of the hard-to-treat nature of pancreatic cancer even small gains are cause to take notice, which is why the approval of Abraxane (paclitaxel) is welcome news. Abraxane is the first treatment to be approved for pancreatic cancer in nearly eight years. Results of the MPACT study, a phase 3 international trial that that examined Abraxane and gemcitabine, found the combo extended overall survival by more than 7 weeks when compared with gemcitabine alone. It also improved one-year survival from 22 percent to 35 percent. Those results helped the Food and Drug Administration decide to approve the regimen for first-line therapy for metastatic disease. The drug was priority review approval back in May and a decision was expected later this month.[See "FDA approves Abraxane for late-stage pancreatic cancer" from FDA.gov]Abraxane is a form of Taxol that is encased in a protein and administered intravenously. This formulation helps reduce severe allergic reaction, and the protein may make it easier for paclitaxel to reach cancer cells than traditional Taxol. Side effects of the combination includes fatigue and peripheral neuropathy.[Blog: Read more about the results of the MPACT study from the 2013 ASCO GU conference]It's believed that Abraxane helps target the stroma, a matrix of cells and molecules that are tightly knit together around the cancer. If Abraxane can weaken the stroma, gemcitabine may have a better chance in targeting the cancer cells.Abraxane is already approved for advanced lung and breast cancers.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of woman with text.
Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun.
Six-time cancer survivor Staci Kirk urges patients to trust their bodies and speak up to ensure their needs are understood and addressed throughout cancer care.
Clinical trials should be designed to ease travel and financial burdens by using local care, telehealth and remote tools, Kimberly Demirhan explained.
Certain treatments may accelerate aging in survivors, but tailored care and healthy habits can help reduce long-term risks, researchers said.
Image of man with text.
Image of woman with text.
Image of man with text.
Related Content